RxDoctor Payments Data

Charles Guillaume

Psychiatric/Mental Health · Snellville, GANPI 1114322419

Payments from drug & device makers

$3,578in general payments, 2019–2025

Across 185 payments — averaging $19.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$758
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$415
  • Vanda Pharmaceuticals Inc.$373
  • Neurocrine Biosciences, Inc.$302
  • Johnson & Johnson$265
  • Teva Pharmaceuticals USA, Inc.$213
  • plus $1K from 15 others

What the payments were for

  • Food & beverage$3,52398%
  • Education$552%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,578 in reported general payments places this provider in the 90th percentile of 900 psychiatric/mental health providers in Georgia.

See all psychiatric/mental health providers in Georgia

Medicare billing

Part B allowed, 2024
$37,712
Medicare patients
66
Services billed
481

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate22$179,413
Austedo XrDeutetrabenazine25$137,829
Aripiprazole78$7,763
Quetiapine Fumarate167$3,304
Bupropion XlBupropion Hcl150$2,341
Paliperidone ErPaliperidone11$1,834
Duloxetine Hcl106$1,823
Clonidine30$1,429
Venlafaxine Hcl ErVenlafaxine Hcl106$1,416
Buspirone Hcl104$1,259
Trazodone Hcl151$1,222
Clozapine39$1,219
Olanzapine21$875
Divalproex Sodium ErDivalproex Sodium14$874
Phenelzine Sulfate14$869

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$302$179,41322 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$213$137,82925 claims
Almatica Pharma LLCSertraline Hcl$20$24623 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 900 psychiatric/mental health providers in Georgia.

Other psychiatric/mental health in Snellville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →